Titre
The potential role of the microbiota in prostate cancer pathogenesis and treatment.
Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Pernigoni, N.
Auteure/Auteur
Guo, C.
Auteure/Auteur
Gallagher, L.
Auteure/Auteur
Yuan, W.
Auteure/Auteur
Colucci, M.
Auteure/Auteur
Troiani, M.
Auteure/Auteur
Liu, L.
Auteure/Auteur
Maraccani, L.
Auteure/Auteur
Guccini, I.
Auteure/Auteur
Migliorini, D.
Auteure/Auteur
de Bono, J.
Auteure/Auteur
Alimonti, A.
Auteure/Auteur
Liens vers les personnes
Liens vers les unités
ISSN
1759-4820
Statut éditorial
Publié
Date de publication
2023-12
Volume
20
Numéro
12
Première page
706
Dernière page/numéro d’article
718
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Publication Status: ppublish
Résumé
The human body hosts a complex and dynamic population of trillions of microorganisms - the microbiota - which influences the body in homeostasis and disease, including cancer. Several epidemiological studies have associated specific urinary and gut microbial species with increased risk of prostate cancer; however, causal mechanistic data remain elusive. Studies have associated bacterial generation of genotoxins with the occurrence of TMPRSS2-ERG gene fusions, a common, early oncogenic event during prostate carcinogenesis. A subsequent study demonstrated the role of the gut microbiota in prostate cancer endocrine resistance, which occurs, at least partially, through the generation of androgenic steroids fuelling oncogenic signalling via the androgen receptor. These studies present mechanistic evidence of how the host microbiota might be implicated in prostate carcinogenesis and tumour progression. Importantly, these findings also reveal potential avenues for the detection and treatment of prostate cancer through the profiling and modulation of the host microbiota. The latter could involve approaches such as the use of faecal microbiota transplantation, prebiotics, probiotics, postbiotics or antibiotics, which can be used independently or combined with existing treatments to reverse therapeutic resistance and improve clinical outcomes in patients with prostate cancer.
PID Serval
serval:BIB_98A4542D9F6F
PMID
Date de création
2023-07-31T11:52:57.856Z
Date de création dans IRIS
2025-05-20T22:05:54Z